Investment Rating - The investment rating for the company is "Buy" and is maintained [8]. Core Views - The company reported a revenue of 565 million yuan for the first half of 2025, a year-on-year decrease of 22.4%, with a net profit attributable to shareholders of -180 million yuan. In Q2 2025, revenue was 313 million yuan, down 20.5% year-on-year, and the net profit was -69 million yuan, showing a slight reduction in losses [2][6]. Summary by Sections Company Overview - The company has faced significant revenue declines in 2024 and the first half of 2025, with no clear signs of a turnaround. The revenue drop in Q2 2025 was slightly less severe than in previous quarters, indicating potential stabilization [11]. Business Segments - In H1 2025, the revenue breakdown by business segments showed: - Life Sciences and Health Environmental revenue of 367 million yuan, down 27.05% year-on-year - Automotive and Other Consumer Goods revenue of 106 million yuan, down 17.85% - Safety Assurance revenue of 58 million yuan, up 10.02% [11]. Future Outlook - The company plans to focus on deepening customer demand, particularly in biomedicine, cosmetics, medical devices, new energy vehicles, special equipment, low-altitude economy, and special industry testing sectors. It aims to improve laboratory capacity utilization and control capital expenditures while optimizing sales incentives and improving operational cash flow [11]. Financial Projections - The company is expected to recover from losses in the latter half of 2025, with projected revenues of 1.752 billion yuan, 1.986 billion yuan, and 2.243 billion yuan for 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 13.7%, 13.3%, and 12.9%. The net profit attributable to shareholders is projected to be 37 million yuan, 152 million yuan, and 248 million yuan for the same years, indicating a gradual recovery in profitability [11].